Plain-English translation of NCT04715568 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether a medication called can help people who were exposed to heavy secondhand smoke at work—like flight attendants before smoking was banned on planes—and now show subtle heart problems. Researchers noticed that people in this situation have unusual blood pressure responses during exercise, even though they don't have obvious heart disease yet. This study will see if the medication can improve how their hearts respond to stress.
Many people were exposed to heavy secondhand smoke for years at work, and as they age, hidden heart problems may be emerging. Doctors want to know if this medication can prevent or slow down heart damage in people with these early warning signs.
You likely qualify if…
You likely don't qualify if…
You would participate in a crossover study lasting about 10 weeks total. First, you'll take either a placebo (inactive) pill or for 4 weeks, then have a 2-week break where you take nothing, then switch to whichever one you didn't take first for another 4 weeks. Throughout the study, you'll likely have exercise tests and heart monitoring to see how the medication affects your heart's response to activity.
AI-generated summary from trial data · Jun 22, 2026 · Not medical advice
United States
Phase
Post-approval monitoring
Sponsor
University of California, San Francisco
Collaborators
Flight Attendant Medical Research Institute
Enrollment target
~100 participants
Started
March 2021
Primary completion
December 2026
Age range
40 Years and older
Last updated on clinicaltrials.gov in July 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Mehrdad Arjomandi, MD
University of California, San Francisco
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.